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Background. Genital tract (GT) inflammation plays a major role in HIV transmission. We aimed to determine the association 
between symptomatic vulvovaginal candidiasis (VVC) and HIV RNA levels in plasma and GTs of HIV-infected women on 
highly active antiretroviral therapy (HAART). 
Method. Women with VVC on HAART were recruited from a primary healthcare clinic in KwaZulu-Natal Province, South 
Africa, between June 2011 and December 2011. VVC was diagnosed clinically, supported by Gram staining and culture of 
genital secretions. HIV RNA load was determined by reverse transcription polymerase chain reaction. CD4+ counts were 
obtained from patients’ medical records.
Results. Plasma HIV RNA was detected in 42 of 60 (70%) patients on HAART. The mean duration (± standard deviation) on 
HAART for these patients was 4.2 (±1.6) months v. 10.7 (±1.4) months for the remaining 18 patients (p<0.0001). Of the 42 
women with detectable plasma HIV RNA, 12 (28.6%) had detectable genital HIV RNA. Plasma HIV RNA levels ranged from 
2.5 (±0.8) to 4.1 (±0.8) log10 copies/ml. Genital HIV RNA levels ranged from 1.4 to 2.5 (±1.1) log10 copies/ml. The adjusted odds 
ratios of plasma HIV RNA levels increased for patients <35 years (p=0.039) and in those with VVC (p=0.008). Detectability 
of HIV in genital secretions was significantly increased in patients with a plasma HIV load ≥10 000 copies/ml (p=0.032) and 
genital absolute counts of neutrophils >10 cells/5 high microscopic fields (p=0.007). 
Conclusion. Given that the majority of women had recently initiated HAART (allowing a high rate of detectable plasma HIV 
RNA), there was insufficient evidence to conclude that VVC was predictive of high plasma HIV RNA levels. It is more likely that 
this cohort of immunosuppressed women were prone to develop VVC. Plasma HIV loads and local genital inflammation were 
predictors of genital HIV detectability. 
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Ulcerative and non-ulcerative lower genital 
tract infections (LGTIs) are thought to play 
a major role in early HIV pathogenesis and 
transmission.[1] LGTIs and plasma HIV viral 
load (VL) partially explain HIV shedding in 
the female genital tract (GT).[1,2] Some studies have suggested 
that changes in the normal microbial flora of the female GT 
contribute to viral shedding.[1-3]
Conditions associated with genital inflammation, particularly 
genital ulcers, have been associated with HIV shedding in the 
GT.[4,5] While the association between non-ulcerative LGTIs 
such as bacterial vaginosis (BV) and GT HIV shedding has 
been well established,[6,7] current studies have shown a less well-
defined relationship between vulvovaginal candidiasis (VVC) 
and HIV shedding. In addition to BV that is not an established 
sexually transmitted infection (STI), vaginitis , an STI caused 
by Trichomonas vaginalis, has also been shown to increase 
the risk of HIV acquisition among women,[8,9] and sexual and 
perinatal HIV transmission. 
Data on the effect of highly active antiretroviral therapy 
(HAART) on vaginal infections among HIV-infected women 
are limited. Factors such as changes in vaginal immunological 
cell populations, cellular activation and cytokine production 
have been reported to alter susceptibility or response to genital 
infections.[10-13] However, it remains unclear whether chemokines 
and cytokines interfere with the activity of polymorphonuclear 
neutrophil (PMN) cells and macrophages in the mucosa, or 























Our objective was to determine the association between symptomatic 
VVC and HIV RNA levels in the plasma and GTs of HIV-infected 
women on HAART. We hypothesised that in HIV-infected women, the 




For this cross-sectional study, consecutive adult (≥18 years) women (all 
HIV-infected) attending Umlazi D clinic, a primary healthcare facility 
in KwaZulu-Natal (KZN) Province, South Africa, between June 2011 
and December 2011 were enrolled after giving informed consent. Data 
on current symptoms suggestive of LGTIs were obtained by means of 
a standard questionnaire. Patients on HAART were defined as those 
receiving treatment with ≥2 nucleoside reverse transcriptase inhibitors 
(NRTIs) and ≥1 protease inhibitor (PI) or non-nucleoside reverse 
transcriptase inhibitor (NNRTI).
A physical examination was performed by the attending medical 
practitioner and signs of LGTIs were noted. Sixty paired plasma and 
cervicovaginal samples were collected from HIV-infected women 
receiving HAART. Patients aged <18 years and those who were 
menstruating or had visible blood contamination of genital samples 
were excluded from the study.
The study was approved by the Biomedical Research Ethics Com-
mittee of the University of KZN (Ref. BE 224/11). Consent forms 
were signed by all participants and confidentiality was maintained 
throughout the study.
Collection and processing of cervico- 
vaginal fluid
A vaginal tampon (8 Ks), Tampax Regular® (Compak), was inserted 
into the vagina, left in situ for 3 minutes, and then placed in a sterile 
container containing 10 ml of phosphate-buffered saline (Oxoid Ltd 
Basingstoke, UK) (pH 6.9). Samples were stored at 4oC for 4 hours prior 
to transport to the laboratory. Vaginal fluid was expressed using an 
auto claved wooden tongue depressor and filtered through 0.22 μm 
Costar Spin-X cellulose acetate filter membranes (Sigma). The filtered 
soluble fraction was aliquoted (in 1 ml cryotubes) and stored at –70oC 
until use.
Measurement of absolute PMN cell counts 
from lower GT samples
A vaginal swab (Becton Dickinson (BD)) was used to collect cells from 
the posterior fornix and to prepare a tissue smear on a glass slide for Gram 
staining. Absolute counts of neutrophils were determined by counting the 
total number of PMN cells in five randomly selected microscopic fields 
under oil immersion (×1 000 magnification) as previously described. The 
scores were as follows: score 1: 1 - 10 PMN cells/5 high microscopic fields 
(HMFs); score 2: 11 - 20 PMN cells/5 HMFs; score 3: >20 PMN cells/5 
HMFs.[14-16]
Diagnostic criteria for symptomatic VVC and 
VVC colonisation
The diagnosis of symptomatic VVC was based on a combination of 
clinical and laboratory criteria (evidence level III, recommendation 
grade B).[17-19] Symptoms suggestive of VVC included vulval pruritus, 
vulval soreness, superficial dyspareunia, and/or non-offensive vaginal 
discharge. Signs included vulval erythema, vulval oedema, fissures, 
excoriation or thick curdy vaginal discharge.
A vaginal swab (BD) taken from the anterior fornix was directly 
plated onto Sabouraud Dextrose agar with chloramphenicol (BBLTM, 
BD) and incubated at 29oC for 48 hours to estimate the relative vaginal 
fungal burden. The numbers of yeast colonies were recorded as the 
number of colonies per plate.[17-19]
In addition to the self-reported symptoms listed above and 
observation of signs suggestive of VVC on physical examination, cases 
of symptomatic VVC were confirmed if one of the following criteria 
was fulfilled (evidence level III, recommendation grade B):[17-19] (i) a 
positive Gram-stain preparation with budding yeasts, pseudohyphae, 
and/or hyphal forms; and (ii) positive culture with either moderate 
(10 - 99 colonies per plate) or heavy (>100 colonies per plate) Candida 
growth.
Participants without symptomatic VVC were defined as: (i) patients 
whose genital specimens were negative for yeasts, pseudohyphae, and/
or hyphal forms of Candida on microscopy, together with negative 
culture; and (ii) patients whose genital specimens were negative for 
yeasts, pseudohyphae on microscopy, and/or hyphal forms of Candida 
together with light Candida growth (<10 colonies per plate). The latter 
was considered to indicate vaginal Candida colonisation rather than 
infection. 
Definitions of HIV-induced 
immunosuppression
As part of the routine management and standard of care in the clinic, 
CD4+ T-cell counts were measured in the blood of all HIV-infected 
patients. The CD4+ T-cell counts used in this study were obtained 
from the past 3 months of measurements in patients’ medical records. 
However, for the purpose of this research, HIV RNA was measured 
from the plasma and cell-free fraction of vaginal secretions using 
Nuclisens Easyq HIV-1 version 2.0 (BioMerieux, France) with a lowest 
detection limit of 20 copies/ml.[20-22]  
Absolute values of CD4+ T-cell counts (cells/µl) were used to 
de ter mine the degree or severity of immunosuppression as per the 
World Health Organization immunological staging criteria: severe 
immunosuppression (<200/µl); advanced immunosuppression (200 
- 349/µl); and mild immunosuppression (350 - 499/µl).[23] HIV VL and 
CD4+ counts were used as markers of disease progression.[23-25] For 
the purpose of this study, plasma viraemia was classified as follows: 
<20 copies/ml (below detectable level of the test used); 20 - 9  999 
copies/ml; and ≥10 000 copies/ml. We also log-transformed HIV loads 
for improved symmetry and included them in multivariate logistic 
regression models as continuous values.
Diagnosis of other LGTIs 
For each study participant, clinical symptoms and signs suggestive of 
LGTIs were recorded and categorised as absent, mild, moderate or 
severe. The diagnosis of BV was made using Nugent’s scores.[15,16] BD 
nucleic acid amplification tests (BD Probetec Assays, Sparks) were 
performed on all cervical swabs to detect Chlamydia trachomatis 
and Neisseria gonorrhoeae. In addition, polymerase chain reaction 
amplifications of DNA isolated from vaginal swabs were performed as 










described previously to detect Mycoplasma 
genitalium, Trichomonas vaginalis and herpes 
simplex virus type 2.[26,27]
Statistical analyses
Categorical variables were expressed as pro-
portions (%), and quantitative (discrete ord inal) 
variables were presented as mean (± standard 
deviation). For univariate analyses, the χ2 test 
was used to compare proportions, while the 
R coefficient was computed to analyse the co-
rrelations between quantitative variables. Fur-
thermore, univariate association between HIV 
RNA detectability (in plasma or vagina) and 
putative risk indicators was defined by odds 
ratios (ORs) with 95% confidence intervals 
(CIs). For multivariate analyses, linear mul tiple 
and logistic regressions were used to identify 
independent determinants associated with 
HIV RNA detectability in the vagina or plasma. 
Multivariate ORs (95% CI) of HIV RNA 
genital/plasma detectability were computed 
after adjusting for confounding fac tors. Excess 
risks were measured using the risk difference 
method.
All tests were two-sided and p<0.05 was 
considered significant. Data were analysed 
us ing SPSS® statistical software version 21.0 
(SPSS Inc., Chicago, USA). 
Results
The median age of the 60 women enrolled in 
the study was 30 years (range 18 - 46). All were 
black Africans.
Plasma HIV RNA was detected in 42 (70%) 
patients. The mean duration on HAART 
was 4.2 (±1.6) months for patients with 
detectable plasma HIV RNA (CD4+ T-cell 
count <350  cells/µl) while for the remaining 
18 patients (CD4+ T-cell count ≥350 cells/µl) 
it was 10.7 (±1.4) months (p<0.0001). 
Of the 42 women with detectable plasma HIV 
RNA, 12 (28.6%) had detectable genital HIV 
RNA. Only one patient had detectable genital 
HIV RNA in the absence of detectable plasma 
HIV RNA. Plasma HIV RNA levels ranged 
from 2.5 (±0.8) log10 copies/ml to 4.1 (±0.8) 
log10 copies/ml. Genital HIV RNA levels ranged 
from 1.4 log10 copies/ml to 2.5 (±1.1) log10 
copies/ml (Table 1). Eight patients out of 12 
(66.7%) with detectable genital HIV RNA had 
plasma HIV loads >10 000 copies/ ml, while 
the remaining pa tients had plasma HIV loads 
of between 20 and 9  999 copies/ ml. Fig. 1 
shows the distribution of plasma HIV loads 
and genital HIV RNA detectability according 
to duration of HAART. 
All patients were on HAART regimen 1, 
namely two NRTIs and one NNRTI. No 
patient received PIs. 
The univariate analysis (Table 2) showed a 
significant association between symptomatic 
VVC and plasma HIV RNA detect ability 
(p=0.006), and patients who complained of 
symp toms suggestive of symptomatic VVC 
had significantly increased plasma HIV RNA 
levels (p=0.039). In addition, a recent history 
(within the past 3 months) of STIs (p=0.035) 
and patients age <35 years (p=0.018) were 
also significantly associated with detectable 
HIV RNA in the plasma. Furthermore, 
the pre sence of both advanced and severe 
HIV-associated immunosupression was 
sig nificantly asso ciated with HIV RNA 
detectability in the plasma (p<0.0001). In 
contrast, no patient with a CD4+ T-cell count 
Table 1. HIV RNA levels in plasma and GT by HAART duration (N=60)
HAART duration (months) Patient groups (n)
VL in plasma (log10 copies/ml), 
mean (±SD)*
VL in vagina (log10 copies/ml), 
mean (±SD)*
0 - 3 1A (n=8/21) 4.1 (±0.8) 2.5 (±1.1)
1B (n=13/21) 3.3 (±1.4) <1.3 (not detectable)
4 - 9 2A (n=4/21) 2.5 (±0.9) 1.6 (±0.5)
2B (n=17/21) 2.9 (±1.1) <1.3 (not detectable)
≥10 3A (n=1/18) <1.3 (not detectable) 1.4
3B (n=17/18) <1.3 (not detectable) <1.3 (not detectable)
GT = genital tract; HAART = highly active antiretroviral therapy; VL = viral load; SD = standard deviation. 
*ANOVA p-value, p<0.0001.
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Fig. 1. Distribution of plasma HIV loads and genital HIV RNA detectability among HAART recipients 
(n=60). (HAART = highly active antiretroviral therapy.)












≥350 cells/µl had detectable plasma HIV 
RNA. 
In the multivariate analysis (Table 3), logistic 
regression was used to identify independent 
determinants of HIV RNA levels in plasma 
after adjusting for univariate confounding 
factors (presenting complaints and recent 
history of STIs). CD4+ T-cell counts were 
not included in the logistic regression model 
because all patients with detectable plasma 
HIV RNA had either advanced or severe 
immunosupression. 
Multivariate analysis showed that a cur-
rent episode of symptomatic VVC was in de-
pendently (p=0.008) associated with detectable 
HIV RNA in the plasma. It was also found that 
HIV-infected women aged <35 years were 
more likely to have higher HIV RNA levels 
in their plasma than women aged ≥35 years 
(p=0.039) (Table 3). 
Factors associated with 
genital HIV RNA shedding 
Of the 42 women with detectable plasma HIV 
RNA, 12 (28.6%) had detectable levels of HIV 
RNA in cell-free vaginal fluid. 
Table 4 shows univariate factors associated 
with genital HIV RNA detectability among 
the patients. Women with a recent history 
of vaginal discharge syndrome (p=0.05) and 
genital ulcer syndrome (p=0.038) were more 
likely to have detectable HIV RNA in their 
GTs (Table 4). However, the data showed no 
association between gonococcus, VVC or BV 
and genital HIV shedding.
Women with a neutrophil cell count score 
of >1 had a five-fold higher risk (OR 5.3, 95% 
CI 1.6 - 17.2; p=0.004) of having detectable 
HIV RNA in their GTs than women with 
a neutrophil cell count score of 1. A recent 
history of use of broad-spectrum antimicrobial 
agents was shown to be associated with 
Table 2. Univariate analysis of factors associated with plasma HIV 
RNA levels in HIV-positive women receiving HAART (N=60)
Associated factors
Detectable plasma 
HIV RNA, n (%) p-value
Age groups (years) 0.018
18 - 24 11 (84.6)
25 - 34 25 (75.8)
≥35 6 (42.9)
Symptomatic VVC  




Presenting complaints  
(OR 5.7, 95% CI 0.9 - 34.7)
0.039
Group 1 (vulval itching, soreness  
and discharge)
40 (74.1)
Group 2 (lower abdominal pain, vaginal 
discharge)
2 (33.3)
Recent history (past 3 months) of STIs 0.035
Vaginal discharge syndrome 26 (78.8)
Genital ulcer syndrome 6 (85.7)
No STI diagnosed 10 (50.0)
CD4+ T-cell count (cells/µl) <0.0001
<200 22 (100)
200 - 349 20 (100)
≥350 0 (0)
Genital HIV load categories (copies/ml) 0.062
≥10 000 2 (100)
20 - 9 999 10 (90.0)
<20 30 (65.2)
Genital absolute neutrophil counts 0.095
>20 cells/5 HMFs 12 (60.0)
11 - 20 cells/5 HMFs 13 (92.9)
1 - 10 cells/5 HMFs 17 (65.4)
HAART = highly active antiretroviral therapy; VVC = vulvovaginal candidiasis; OR = odds ratio;  
CI = confidence interval; STIs = sexually transmitted infections; HMFs = high microscopic fields.
Table 3. Independent determinants of plasma HIV RNA levels in HIV-infected women receiving HAART*(N=60)
Independent variables β-coefficient Standard error Wald χ2 OR (95% CI) p-value
Age groups (years) 0.039
18 - 24 2.328 1.043 4.978 10.3 (1.3 - 79.2) 0.026
25 - 34 1.765 0.789 5.001 5.8 (1.2 - 27.5) 0.025
≥35 Reference 1
Symptomatic VVC
Yes 2.082 0.790 6.943 8 (1.7 - 37.7) 0.008
No Reference 1
Constant –1.236 0.719 2.954 0.086
HAART = highly active antiretroviral therapy; OR = odds ratio; CI = confidence interval; VVC = vulvovaginal candidiasis. 
*Adjusted for presenting complaints and recent history of sexually transmitted infections. 










detectable HIV shedding in the univariate 
analysis (p=0.048) (Table 4). 
In the multivariate analysis, after adjusting 
for the presence of univariate confounding 
factors (use of broad-spectrum antibiotics 
and recent history of STIs), an increase in the 
vaginal absolute neutrophil counts (p=0.007) 
and plasma HIV RNA levels (p=0.032) 
remained independently associated with 
genital HIV shedding (p=0.005) (Table 5; 
Fig. 3). Plasma VL (20 - 9  999 copies/ml) 
tended to correlate positively with genital HIV 
shedding, but this correlation did not reach 
statistical significance (p=0.166). However, 
plasma HIV RNA levels ≥10  000 copies/ml 
(p=0.032) were independently associated with 
genital HIV RNA detectability to a detection 
limit of 20 copies/ml (Table 5). 
Furthermore, when using transformed 
log10 HIV RNA values, correlations between 
plasma HIV RNA levels and genital PMN cell 
counts >10 cells/5 HMFs with detectability of 
genital HIV RNA shedding showed significant 
associations (Fig. 3). Detectability and levels 
of mean log10 HIV RNA in the vaginal fluid 
increased with the increase of plasma HIV 
RNA levels (log10) (r=0.2, R
2=0.04; p=0.032) 
(Fig. 3A) and increased absolute counts of 
genital PMN cells (r=0.21, R2=0.045; p=0.007) 
(Fig. 3B).
Discussion
Inflammation of the GT during LGTIs, 
particularly STIs and BV, has been reported 
to predict increased plasma VLs in HIV-
infected women.[28,29] In this study, given that 
the majority of women had just initiated 
HAART (and therefore had a high rate of 
detectable plasma HIV RNA and low CD4+ 
counts), there was insufficient evidence to 
demonstrate that VVC was predictive of high 
plasma HIV RNA levels. Although cause and 
effect was difficult to unravel in the current 
study design, it seemed more likely that the 
observed higher level of immunosuppression 
among the study participants influenced the 
occurrence of VVC. In addition, plasma HIV 
loads and local genital inflammation were 
predictors of genital HIV shedding, but did 
not predict the presence of VVC. Women aged 
<35 years were more likely to have increased 
plasma HIV RNA levels than women aged 
≥35 years. A previous study of the relationship 
between age and plasma VL in HIV-infected 
individuals showed that older ages (>50 years) 
compared with individuals aged 18 - 39 years 
were associated with lower levels of HIV-1 


































Fig. 2. Distribution of vaginal HIV RNA detectability by PMN cell groups (p=0.005). (PMN=polymorphonuclear 




























Dependent variable: CVL RNA (log10)








Fig. 3. Variation of genital HIV RNA levels as predicted by (A) plasma HIV loads (r=0.2, R2=0.04; p=0.032)  and (B) 
genital PMN cells (r=0.21, R2=0.045; p=0.007). (CVL = cervicovaginal lavage; PMN = polymorphonuclear 
neutrophil.)












antiretroviral therapy use, regimen adherence 
and disease stage. One possible explanation 
of the relationship between the plasma VL 
and age category would be immunological 
differences. It has been shown that older age 
was associated with an increase in peripheral 
CD4+ and CD8+ T lymphocytes and that thy-
mic involution was associated with this  effect, 
leading to lower expression of plasma HIV-1 
RNA.[30]
Studies of the association between HIV VL 
in the female GT and in the plasma have 
shown conflicting results. In this study, 28.6% 
of the patients shed HIV in their genital 
secretions. This finding is consistent with pre-
vious reports of HIV-1 DNA and/or RNA 
being detected in the GT of 28 - 60% of HIV-
1-seropositive women.[29,31-33] These previous 
studies also demon strated that genital HIV-1 
was more likely to be detected from either the 
cell-associated fraction of the cervicovaginal 
fluid or whole genital fluid than from cell-
free vaginal fluid.[29,31-33] Although within the 
published range, our finding of a relatively 
low frequency of viraemia in the GT of our 
study population may be attributed to the type 
of sample that was analysed (measurement 
of HIV loads in cell-free fraction alone). It is 
difficult to conclude that antiretroviral therapy 
significantly lowered HIV RNA levels in genital 
secretions, given the fact that the women had 
just started HAART. 
We found that women with a recent history 
of vaginal discharge syndrome and genital 
ulcer syndrome were more likely to shed HIV 
in their GTs than women without a recent 
history of such STIs. However, after testing 
for the most common causes of LGTIs, none 
of the tested aetiological agents of vaginal 
discharge syndrome (VDS) showed significant 
association with genital HIV shedding. 
The fact that HIV VL was only measured 
from the cell-free fraction of genital secretions 
may account for the lack of an association 
between GT viraemia and tested causes of 
VDS, including symptomatic VVC.
We identified two independent factors asso-
ciated with HIV RNA shedding in the vagina; 
of these factors, one had been previous ly 
identi fied, namely the associa tion between 
high er levels of plasma HIV RNA and the 
ability to detect HIV in genital secretions.[31,34] 
Consistent with previous studies, we found 
that genital HIV RNA detectability strongly 
correlated with plasma HIV VL, but that these 
correlations were weak, except when plasma 
HIV VL was ≥10 000 copies/ml. Other studies 
have suggested that compartmentalisation of 
the vaginal immune response from systemic 
immunity may account for such weak 
correlations.[35,36] This might also be explained 
by the fact that HIV VL was only measured 
from the cell-free fraction of the genital 
secretions.
Table 4. Univariate analysis of factors associated with genital HIV 




RNA n (%) OR (95% CI) p-value
Current STIs
Trichomonas vaginalis 0.7 (0.3 - 2.1) 0.554
Positive 6 (25.0)
Negative 18 (31.6)
Chlamydia trachomatis 0.8 (0.2 - 2.9) 0.781
Positive 4 (26.7)
Negative 20 (30.3)
Neisseria gonorrhoeae 1.2 (0.3 - 5.3) 0.796
Positive 3 (33.3)
Negative 21 (29.2)
Mycoplasma genitalium 0.5 (0.1 - 4.1) 0.478
Positive 1 (16.7)
Negative 23 (30.7)
Herpes simplex virus type 2 0.7 (0.6 - 0.8) 0.183
Positive 0 (0)
Negative 24 (31.2)
Other lower GT infections
VVC 1.2 (0.5 - 3.2) 0.649
Infection 13 (32.5)
Colonisation 12 (27.9)
BV 1.2 (0.4 - 4.3) 0.747
Positive 21 (30.9)
Negative 4 (26.7)
Recent history (past 3 months) of 
STIs
Vaginal discharge syndrome 14 (36.8) 3.2 (1.0 - 10.1) 0.050
Genital ulcer syndrome 6 (46.2) 4.6 (1.1 - 19.7) 0.038
No STI 5 (15.6) 1
Genital absolute neutrophil counts 5.3 (1.6 - 17.2) 0.004
Score >1 21 (42.0)
Score = 1 4 (12.1)
Plasma HIV RNA levels <0.0001
≥10 000 copies/ml (≥4 log10) 8 (100)
20 - 9 999 copies/ml (1.3 log10 - 
3.99 log10)
4 (11.8)
<20 copies/ml (<1.3 log10) 1 (5.6)
Antibiotic use 3.2 (1.01 - 10.60) 0.048
Yes 21 (36.8)
No 4 (15.4)
HAART = highly active antiretroviral therapy; OR = odds ratio; CI = confidence interval; STIs = sexually transmitted infections; 
GT = genital tract; VVC = vulvovaginal candidiasis; BV = bacterial vaginosis.










We also found that the absolute neutrophil count in the genital 
mucosa was another factor associated with genital HIV RNA shed-
ding. Previous studies have shown the role of genital inflammation in 
HIV-1 shedding. [8,37] It has been reported that following HIV-1 infection, 
cytokines and chemokines are produced by infected leukocytes 
that attract more target cells for HIV-1 infection and allow further 
stimulation of the expression of HIV-1 via toll-like receptors.[8-10] In this 
study, we found that the number of neutrophils in the female GT was 
associated with HIV shedding. Of particular interest, our study did not 
show an association between symptomatic VVC and HIV shedding in 
the vagina. In addition to the fact that HIV was quantified only in the 
cell-free fraction of genital fluids, this lack of association could also be 
the result of strong recruitment of neutrophils in the vagina – various 
immunomodulators have been reported as associated with the anti-
Candida activity of neutrophils.[35,36] Cytokines such as TNF-α and IL-8 
increase the activity of neutrophils against Candida albicans.[35] Gumbi 
et al.[36] reported that women who were detectably shedding HIV-1 in 
the GT had significantly increased cervical levels of TNF-α, IL-1β, IL-6 
and IL-8 compared with women who were not detectably shedding 
the virus. It remains unclear from our observations whether or not 
symptomatic VVC is more likely to occur among HIV-infected women 
who are not detectably shedding the virus. 
Another possible reason why symptomatic VVC was not associated 
with genital HIV shedding could be the challenges associated with the 
diagnosis of VVC. A clinical definition of VVC could be problematic 
even when microscopic tests and cultures of genital samples are used 
to support the clinical diagnosis. While Gram staining has a sensitivity 
of 75% in supporting the clinical diagnosis of VVC, up to 30% of 
women with significant chronic symptoms suggestive of VVC may have 
negative cultures at presentation.[38]
 
Limitations
Limitations of this study include its cross-sectional design and small 
sample size. In addition, the impact of factors such as HAART regimen 
composition, adherence to HAART and effects of HIV disease stages 
were not explored. 
The majority of our patients had just started HAART. Therefore, it 
is difficult to say that they were not successfully treated. A plausible 
hypothesis for why we did not find an association between VVC and 
genital HIV shedding could have been the fact that HIV RNA was 
only measured from the cell-free fraction of cervicovaginal secretions. 
If both HIV complementary DNA and HIV RNA had been measured, 
results could have been different. This might also explain why plasma 
HIV loads <10 000 copies/ml were not significantly associated with 
genital HIV shedding in the multivariate logistic analysis. 
Finally, findings present insufficient evidence of the true impact of 
VVC on HIV RNA levels in plasma and genital secretions. 
Conclusions
Identified factors associated with HIV RNA loads in plasma and female 
genital secretions were consistent with previously published factors 
from the literature. Of particular note, our study did not have enough 
evidence to demonstrate that symptomatic VVC was predictive of 
higher levels of HIV RNA in plasma and genital secretions. However, 
unlike STIs and BV, symptomatic VVC was less likely to occur among 
HIV-infected women who were detectably shedding the virus in 
their lower GT, possibly owing to the observed strong recruitment 
of neutrophils that possess anti-Candida activity or the challenges 
associated with the diagnosis of VVC. About 70% of the study 
population had detectable HIV RNA in their plasma; this finding was 
supported by the fact that all these patients had a CD4+ T-cell count 
<350 cells/µl, which is a marker of systemic immunosuppression. It is 
highly likely that the observed higher rate of HIV RNA detectability 
was purely the result of immunosuppression and that the associated 
high prevalence of symptomatic VVC could have been a consequence 
of overall immunosuppression. Further studies are required to 
ascertain the impact of VVC on HIV RNA levels in plasma and genital 
secretions. 
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